Biologická léčba 2024 I
Části
| Zobrazit detail | ||||
|---|---|---|---|---|
| N006/24/V00036232/001 | I. Erenumab (ATC N02CD01) | Antineoplastika | Neukončen | |
| N006/24/V00036232/002 | II. Sekukinumab (ATC L04AC10) | Antineoplastika | Neukončen | |
| N006/24/V00036232/003 | III. Dabrafenib (ATC L01EC02) | Antineoplastika | Neukončen | |
| N006/24/V00036232/004 | IV. Lapatinib (ATC L01EH01) | Antineoplastika | Neukončen | |
| N006/24/V00036232/005 | V. Trametinib (ATC L01EE01) | Antineoplastika | Neukončen | |
| N006/24/V00036232/006 | VI. Ribociklib (ATC L01EF02) | Antineoplastika | Neukončen | |
| N006/24/V00036232/007 | VII. Siponimod (ATC L04AE03) | Antineoplastika | Neukončen | |
| N006/24/V00036232/008 | VIII. Fingolimod (ATC L04AE01) | Antineoplastika | Neukončen | |
| N006/24/V00036232/009 | IX. Ofatumumab (ATC L04AG12) | Antineoplastika | Neukončen |